Boston Pharmaceuticals Widens Opportunities With New GSK Assets
Company In-Licenses Oncology, Neurology Drugs
In an interview, CEO Rob Armstrong said the company has created “a lot optionality” for how it can develop the programs it takes on from the big pharma’s portfolio management.
You may also be interested in...
Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.
The US firm is getting its hands on eight programs from two of the world's leading drug makers, seeing an opportunity in areas such as antibiotics where solutions may be more likely to come from biotech rather than big pharma.
Christopher Viebacher's new venture Boston Pharmaceuticals was established with enough capital - $600 million - to scour thousands of Phase-I ready programs and build a portfolio of 20 to 25 early-stage drug candidates that it will attempt to de-risk then sell or license to interested partners